Integrilin (eptifibatide) / Takeda - LARVOL DELTA

RAPID-ONSET PROFOUND THROMBOCYTOPENIA WITH HEMORRHAGIC SHOCK FOLLOWING EPTIFIBATIDE ADMINISTRATION (CHEST 2026) - No abstract available

Hematological Disorders • Thrombocytopenia

EPTIFIBATIDE BRIDGING FOR URGENT SURGERY 14 DAYS POST-PCI: A CASE REPORT (CHEST 2026) - No abstract available

Case report • Clinical • Surgery • Acute Coronary Syndrome • Cardiovascular

Injectable antiplatelet therapies in acute coronary syndromes: Current status and Emerging Therapies. A position paper of the Task Force of Antithrombotic therapy of the ACVC. (PubMed, Eur Heart J Acute Cardiovasc Care) - "Intravenous aspirin is used widely in patients with ACS, while the absorption of oral P2Y12 inhibitors is often delayed, and the intravenous P2Y12 inhibitor cangrelor can achieve almost complete platelet inhibition within minutes. While use of the glycoprotein IIb/IIIa inhibitors (GPI) eptifibatide and tirofiban is decreasing, typically reserved for thrombotic complications or no reflow following PCI, recently zalunfiban, a novel subcutaneously administered GPI has been shown to improve reperfusion before revascularisation in patients with STEMI when given at first medical contact. In this review, we dicuss the rationale and potential benefits of injectable antiplatelet medications, including currently available agents and those in development or being tested in clinical trials. While the benefit of injectable medications on hard clinical endpoints such as major adverse cardiac events remains unclear for an allcomers ACS population, there is emerging data that these..."

Journal • Acute Coronary Syndrome • Anesthesia • Cardiovascular • Myocardial Infarction

Transmembrane Protein Disulfide Isomerase TMX3 Potentiates Platelet Aggregation and Arterial Thrombosis in Mice. (PubMed, Arterioscler Thromb Vasc Biol) - "Calcium ionophore, eptifibatide, ADP, and apyrase were used to investigate the regulatory mechanisms of TMX3 in platelet granule secretion...Recombinant catalytically inactivated TMX3 protein inhibited platelet aggregation and ATP release and significantly reduced platelet accumulation and fibrin deposition in the laser-induced thrombosis model, whereas recombinant wild-type TMX3 protein neither enhanced human platelet aggregation and ATP release nor rescued the impaired aggregation and ATP release of TMX3-deficient platelets. Our data highlight a critical role for TMX3 in platelet function and thrombus formation by interacting with αIIbβ3 integrin and directly regulating platelet granule secretion."

Journal • Preclinical • Cardiovascular • Hematological Disorders • Thrombosis

Pharmacovigilance analysis of glycoprotein IIb/IIIa inhibitors: A FAERS-based signal detection study. (PubMed, Medicine (Baltimore)) - "This study compares the safety signals of 3 glycoprotein IIb/IIIa inhibitors (GPIs) - tirofiban, abciximab, and eptifibatide - using the US Food and Drug Administration Adverse Event Reporting System, aiming to guide clinical application. Abciximab signals highlight oropharyngeal, otorhinolaryngologic, and urinary tract mucosal surfaces. These findings support pharmacovigilance and warrant validation through prospective studies, with the understanding that all reported associations are based on statistical signals from a spontaneous reporting system and do not establish causality."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pancreatitis • Thrombocytopenia

A Therapeutic Dilemma: Catastrophic ST-Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2-Positive Polycythemia Vera. (PubMed, Clin Case Rep) - "Revascularization was successful, and eptifibatide bridging enabled safe surgery. This case highlights the risks of interruption and the role of bridging therapy."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Polycythemia Vera • Thrombosis • JAK2

Tailoring therapy for acute myocardial infarction and de novo severe immune thrombocytopenia – a case report (ISTH 2026) - "Results The patient received peroral acetylsalicylic acid (300 mg ) and ticagleror (180 mg) and was immediately referred to percutaneous coronary intervention (PCI). During procedure parenteral unfractionated heparin was administered (10000 IU) alongside dilatation manoeuvre in the right coronary artery occlusion with intracardiac eptifibatide delivery (50 mg) due to the vast thrombus...On the 2 nd day of hospitalization peroral antiaggregation therapy was continued and clopidogrel was introduced (75 mg per day) to prevent coronary rethrombosis...Later on, therapeutic doses of fondaparinux were introduced due to atrial fibrillation paroxysms...However, a clear consensus on the treatment in these specific circumstances is needed. Table or Figure Upload (1) Laboratory parameters during the patient's hospitalization Page 2 DOI*10.1016/j.rpth.2026.106584"

Case report • Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Myocardial Infarction • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Development of Novel In Vitro Microfluidic Thrombosis Models Using Anticoagulant-Functionalised Surfaces (ISTH 2026) - "Anticoagulant efficacy was assessed under arterial flow conditions by perfusing recalcified human blood spiked with DiOC 6 and fluorescently labelled fibrinogen, with or without eptifibatide...Conclusions Surface-adsorbed heparin effectively quenches downstream coagulation under arterial blood-flow conditions, making it a valuable and simple addition to microfluidic thrombosis models. DOI*10.1016/j.rpth.2026.105889"

Preclinical • Cardiovascular • Hematological Disorders • Thrombosis

Selective Disruption of β3/Src Interaction by Novel Small Molecules Suppresses Arterial and Venous Thrombosis Without Compromising Hemostasis (ISTH 2026) - "In vivo, both compounds significantly delayed arterial occlusion and reduced venous thrombus extension and weight, comparable to high-dose integrilin and rivaroxaban, respectively, without prolonging bleeding time or increasing blood loss. C109 and C116 more effectively inhibit arterial and venous thrombosis without prolonging bleeding time. Page 4 DOI*10.1016/j.rpth.2026.105569"

Cardiovascular • Hematological Disorders • Thrombosis

High factor VIII concentrations modulate interactions between platelets and von Willebrand factor in vitro (ISTH 2026) - "Experiments used B-domain-deleted recombinant FVIII (simoctocog alfa). Eptifibatide was present during ristocetin ‑ or VWF ‑ activating ‑ nanobody induced platelet agglutination to block integrin-VWF interactions...JTH. https://doi.org/10.1016/j.jtha.2023.09.004 #Platelets #FVIII #VWF #GPIb DOI*10.1016/j.rpth.2026.105208"

Preclinical

Off-Label Use of Ticagrelor in Pediatric Acute Ischemic Stroke Patients (ISTH 2026) - "Case 1 underwent catheter-directed thrombectomy and eptifibatide drip, followed by ASA and clopidogrel. Research on novel antiplatelet agents for the pediatric population is needed. Table or Figure Upload (1) Page 2 DOI*10.1016/j.rpth.2026.105036"

Clinical • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Pediatrics • Vasculitis • CYP2C19

Impact of Using Blended Polymers on the Structural and Functional Attributes of Eptifibatide-Loaded Microspheres. (PubMed, ACS Omega) - "Specifically, polymers with closer IV values were used in this study. The microspheres formulated using blended polymers were compared with those formulated using original/on-shelf polymers, and both sets demonstrated identical performance."

Journal

Commentary: Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data. (PubMed, Front Med (Lausanne)) - No abstract available

Journal • Real-world evidence

Adaptive Antithrombotic Strategy for Tandem Occlusion Stroke: Escalating Therapy After Thrombectomy and Stenting. (PubMed, Diagnostics (Basel)) - "Rescue use of eptifibatide was not significantly associated with symptomatic intracranial hemorrhage; however, a clinically relevant risk cannot be excluded. These findings highlight the importance of tailored antithrombotic strategies in acute ischemic stroke to maintain stent patency while minimizing hemorrhagic complications."

Journal • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

Galectin-3 Binds to the Allosteric Site and Activates Integrins αvβ3, αIIbβ3, and α5β1, and Lactose Inhibits This Activation. (PubMed, Biomolecules) - "RGDfV or eptifibatide inhibited Gal3 binding to αvβ3 and αIIbβ3, respectively, but lactose, a pan-galectin inhibitor, did not inhibit Gal3 binding to integrins...Known anti-inflammatory agents, Ivermectin, NRG1, and FGF1, inhibited integrin activation induced by Gal3 in αvβ3 and αIIbβ3. These findings suggest that Gal3 binding to site 2 may be a potential mechanism of pro-inflammatory and pro-thrombotic action of Gal3."

Journal • Oncology • IL6 • LGALS3 • NRG1

Adjunctive Eptifibatide Administration in ACS Patients Undergoing Percutaneous Coronary Intervention: A Randomized Comparison of Bolus-only Versus Standard Therapy. (PubMed, Am Heart J Plus) - "Most acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are already on dual antiplatelet therapy (aspirin plus clopidogrel). Electrical complications were infrequent and comparable. In ACS patients on dual antiplatelet therapy, bolus-only eptifibatide provides ischemic protection comparable to bolus-plus-infusion while reducing minor bleeding, supporting a simplified adjunctive strategy in high thrombotic-risk patients undergoing PCI."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Study on the treatment of early neurological deterioration in patients with perforating artery infarction using GPⅡb/Ⅲa receptor antagonists (ChiCTR) - P=N/A | N=100 | Sponsor: Emergency General Hospital; Emergency General Hospital

New trial • CNS Disorders • Vascular Neurology

EPISTROKE-II: A prospective, multicenter, double-blind, randomized controlled trial of early adjunctive eptifibatide following intravenous thrombolysis in acute disabling stroke due to non-large vessel occlusion (ChiCTR) - P3 | N=1016 | Sponsor: The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University

New P3 trial • Cardiovascular • Ischemic stroke

Spontaneous Proximal Middle Cerebral Artery Dissection due to Stimulant-associated Vascular Injury (AAN 2026) - "Given the severity of her deficits, she received IV Tenecteplase and was transferred for thrombectomy...She was treated with IV eptifibatide and transitioned to aspirin 81 mg daily...Given her use of bupropion and Adderall, stimulant-associated vascular injury was considered...In our unique case, a potential cause may have been stimulant-associated vascular injury, as amphetamine derivatives have been linked to vasculopathy, vasospasm, and vessel wall injury. This case highlights IAD as a rare but important cause of stroke in the young and raises stimulant-associated vascular injury as a possible contributor."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • General Anxiety Disorder • Giant Cell Arteritis • Hematological Malignancies • Immunology • Ischemic stroke • Thrombosis

The efficacy and safety of eptifibatide in patients with minor strokes, a multicenter, double-blined, double-dummy, randomized controlled trial (ChiCTR) - P=N/A | N=1916 | Sponsor: The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University

New trial • Cardiovascular • Ischemic stroke

Therapeutic Plasma Exchange for Uncontrollable Bleeding After Platelet Inhibition with Ticagrelor: A Report of 2 Cases. (PubMed, Am J Case Rep) - "He underwent emergency percutaneous coronary intervention and was started on dual antiplatelet therapy (aspirin 81 mg/day, and ticagrelor 90 mg twice daily)...Our second case was a 66-year-old man who received single doses of ticagrelor (180 mg) and eptifibatide (180 mcg/kg) during an attempted PCI...Platelet reactivity increased immediately following the procedure; bleeding was stabilized, and no further blood products were required after postoperative day 1. CONCLUSIONS TPE may be an effective novel option for emergency removal of circulating ticagrelor in refractory bleeding cases."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Radiographic Bleeding Risk After Carotid Stenting for Stroke: Eptifibatide and a Predictive Score (SCCM 2026) - "Eptifibatide was associated with increased radiographic but not symptomatic ICH. This bleeding risk appeared linked to higher stroke severity and more urgent intervention in the eptifibatide+DAPT group. A risk score may help guide individualized antiplatelet decisions during emergent carotid stenting."

Cardiovascular • Cerebral Hemorrhage • Diabetes • Hematological Disorders • Ischemic stroke • Metabolic Disorders

Comparative Study of Hemorrhagic Conversion After Treatment With Eptifibatide vs Oral DAPT (SCCM 2026) - "Eptifibatide was not observed to increase rates of adverse outcomes compared to PO DAPT post-thrombolytics and MT in patients with AIS. Further research is needed to determine the impact of eptifibatide utilization in known, asymptomatic hemorrhagic conversion patients post-thrombolytics and MT."

Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data. (PubMed, Front Med (Lausanne)) - "The study also highlighted the importance of early detection of adverse reactions to Eptifibatide. This research provides insights into both known and potential adverse reactions associated with Eptifibatide in real-world clinical use, offering additional safety information for clinicians when prescribing Eptifibatide for ARDS treatment."

Journal • Real-world evidence • Acute Coronary Syndrome • Acute Respiratory Distress Syndrome • Allergy • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Hypotension • Myocardial Infarction • Pancreatitis • Pulmonary Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia

ACUTE STEMI FROM CORONARY EMBOLISM IN A YOUNG MALE WITH POLYCYTHEMIA VERA (ACC 2026) - "He was started on aspirin, ticagrelor, statin, and ezetimibe; eptifibatide was stopped due to bleeding...Due to recurrent arterial events, apixaban was started, aspirin stopped, ticagrelor continued. Heart failure therapy and hydroxyurea were continued... PV can cause embolic STEMI without coronary disease. Early recognition and tailored therapy led to stable recovery."

Cardiovascular • Chronic Eosinophilic Leukemia • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hypertension • Myocardial Infarction • Polycythemia Vera • Thrombosis • JAK2